Izrael - hebrejščina - Ministry of Health

sanofi - aventis israel ltd - leflunomide 100 mg - film coated tablets - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

Izrael - hebrejščina - Ministry of Health

neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejščina - Ministry of Health

neopharm scientific ltd - lenalidomide 10 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejščina - Ministry of Health

neopharm scientific ltd - lenalidomide 15 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejščina - Ministry of Health

neopharm scientific ltd - lenalidomide 25 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejščina - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib

Izrael - hebrejščina - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib

Izrael - hebrejščina - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 3 mg - ixazomib

Izrael - hebrejščina - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 3 mg - ixazomib

Izrael - hebrejščina - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 4 mg - ixazomib